Equity Overview
Price & Market Data
Price: $0.0348
Daily Change: +$0.0127 / 36.49%
Daily Range: $0.0348 - $0.0418
Market Cap: $160,804
Daily Volume: 4,173
Performance Metrics
1 Week: -34.03%
1 Month: -82.13%
3 Months: -79.65%
6 Months: -94.22%
1 Year: -98.53%
YTD: -79.65%
Company Details
Employees: 7
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.